Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

@article{Lynch2004ActivatingMI,
  title={Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.},
  author={Thomas J. Lynch and Daphne W Bell and Raffaella Sordella and Sarada Gurubhagavatula and Ross A. Okimoto and Brian W. Brannigan and Patricia L. Harris and Sara M. Haserlat and Jeffrey G. Supko and Frank G. Haluska and David N. Louis and David C. Christiani and Jeffrey Settleman and Daniel A. Haber},
  journal={The New England journal of medicine},
  year={2004},
  volume={350 21},
  pages={
          2129-39
        }
}
BACKGROUND Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown. METHODS We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who… 

Figures and Tables from this paper

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

TLDR
In vitro characterizations of NSCLC cell lines and host cell lines transfected with these mutant and wild-type EGFR show that most cell lines with mutated EGFR are growth-inhibited by 10- to 100-fold lower concentrations of gefitinib and erlotinib compared with wild- type EGFR.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

TLDR
The case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefItinib, where the DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  • D. BellT. Lynch D. Haber
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib, and the combination of gefithinib with chemotherapy does not improve survival in patients with these molecular markers.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

TLDR
EG FR TK mutational analysis is a novel predictive test for selecting lung adenocarcinoma patients for targeted therapy with EGFR TK inhibitors.

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

  • A. HataH. Yoshioka N. Katakami
  • Biology, Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
Gefitinib has different efficacy according to the type of complex EGFR mutations, and patients with Del-19 and L858R mutations may benefit more from gefit inib than other types of complex mutations.

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

TLDR
This review focuses on characterized mechanisms of resistance to the EGFR TKIs and efforts to overcome the problem of resistance aimed at improving the therapy of patients with NSCLC.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

TLDR
Endogenous EGFRs expressed in NSCLC cell lines positive for both EGFR mutation and amplification were found to be constitutively activated as a result of ligand-independent dimerization and the patterns of both EGfr amplification and EGFR autophosphorylation were shown to differ between cell lines harboring the two most common types of EGFR mutations.
...

References

SHOWING 1-10 OF 32 REFERENCES

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

TLDR
Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

TLDR
Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  • M. HeinrichC. Corless J. Fletcher
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib.

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

TLDR
The determination of multiple EGFR mutations within individual tumors suggests that glioblastomas with EGFR amplification have the capacity to produce a variety of functionally distinct EGFRs.

Mutations of the BRAF gene in human cancer

TLDR
BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  • R. HerbstA. Maddox P. LoRusso
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Rash and diarrhea, generally mild and tolerable at doses <or= 600 mg/d, were DLTs at 800mg/d (maximum-tolerated dose), and Pharmacokinetic analyses confirmed suitability of once-daily oral dosing.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

  • J. AlbanellF. Rojo J. Baselga
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
ZD1839 inhibits EGFR activation and affects downstream receptor-dependent processes in vivo and strongly supports pharmacodynamic assessments to select optimal doses instead of a maximum-tolerated dose for definitive efficacy and safety trials.

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

TLDR
The HER2/neu gene is a member of the Type I receptor tyrosine kinase (RTK) group which is one of the subfamilies in the proto oncogene family and encodes a 185kD surface membrane receptor protein which is expressed in a wide variety of tissues.